Evidence map›Paper›PMID 34306873›Full record

ArticleCureus2021

Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy.

Si Li, Nishant Sharma, Daniel Kazmierski, Mohammad Asim Amjad, Yishan Dong, Yichen Wang, Namita Sharma, Srinivasarao Ramakrishna, Pius Ochieng

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Si LiInternal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Nishant SharmaInternal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Daniel KazmierskiInternal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Mohammad Asim AmjadInternal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Yishan DongInternal Medicine, Rochester Regional Health, Rochester General Hospital, Rochester, USA.
Yichen WangMercy Internal Medicine Service, Trinity Health of New England, Springfield, USA.
Namita SharmaHematology and Oncology, Geisinger Commonwealth School of Medicine, Scranton, USA.
Srinivasarao RamakrishnaPulmonary and Critical Care Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA.
Pius OchiengPulmonary and Critical Care Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.

Indexed as

acute hypoxemic respiratory failurediffuse alveolar hemorrageground-glass opacityimmune check-point inhibitorurothelial malignancy

Identifiers

PMID34306873
PMCPMC8294017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.